Endometrial Cancer Research Reagents

Endometrial cancer is the sixth most common cancer in women worldwide, with rising incidence linked to increasing obesity rates. The TCGA-derived molecular classification (POLE ultramutated, MSI-H, copy-number low, copy-number high/p53-abnormal) has replaced traditional histologic typing as the primary prognostic framework. Dostarlimab (anti-PD-1) with chemotherapy is now standard first-line for dMMR/MSI-H disease, while pembrolizumab with lenvatinib serves the pMMR/MSS population.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Endometrial Cancer Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in endometrial cancer. TCGA molecular classification (dMMR, p53-abnormal), immune checkpoint, and targeted therapy axes. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key endometrial cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

MMR Proteins (MLH1, MSH2, MSH6, PMS2) — Mismatch repair deficiency (dMMR) occurs in 25–30% of endometrial cancers and is the primary molecular classifier for immunotherapy eligibility. Anti-MLH1, MSH2, MSH6, and PMS2 antibodies enable the IHC-based four-antibody panel that serves as a surrogate molecular classification approach recommended by international guidelines.
→ Browse MMR pathway antibodies

p53 (TP53) — Aberrant p53 expression (diffuse nuclear overexpression or complete absence) identifies the copy-number high/p53-abnormal molecular subtype with the worst prognosis. Anti-p53 IHC serves as a practical surrogate for TP53 mutation sequencing in the molecular classification workflow and predicts aggressive serous-like behavior.
→ Browse p53 antibodies & proteins

PD-L1 (CD274) — PD-L1 expression profiling supports immunotherapy response prediction in endometrial cancer, particularly in the dMMR/MSI-H subgroup where checkpoint inhibitors show exceptional activity. Anti-PD-L1 antibodies enable CPS scoring, tumor microenvironment characterization, and combination immunotherapy research.
→ Browse PD-L1 antibodies & proteins

References

1. Mirza MR, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145-2158. DOI

2. Makker V, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437-448. DOI

3. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. DOI

4. Oaknin A, et al. Clinical activity and safety of dostarlimab in patients with recurrent or advanced dMMR/MSI-H endometrial cancer. J Clin Oncol. 2021;39(14):1561-1572. DOI